QB3
Overview
QB3 is a nonprofit research and technology commercialization institute affiliated with the University of California campuses at Berkeley, San Francisco, and Santa Cruz . QB3 supports early-stage commercialization in biotech and pharma, and conducts basic and applied research . The institute connects scientists to each other and to resources, enabling them to bring new technologies to market . QB3 operates a network of incubators, providing laboratory space for early-stage biotech companies .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Kopra Bio | Jan 2025 | Grant | Co-investor |
| Gravitas Medical, Inc. | Sep 2022 | Series A Extension | Co-investor |
| Halo Biosciences | Nov 2019 | Accelerator | Co-investor |
| Allysta Pharmaceuticals | Feb 2017 | Accelerator | Co-investor |
| Symic Bio | Dec 2015 | Series A Extension | Co-investor |
For institutional investors. Book with your work email.
Key People
David Schaffer
Director
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is QB3 based?
QB3 is headquartered in Berkeley, California, United States.
When was QB3 founded?
QB3 was founded in 2000.
How many portfolio companies does QB3 have?
QB3 has 8 portfolio companies in Caplight's dataset.
What are some companies in QB3's portfolio?
Recent investments visible on Caplight include Kopra Bio, Gravitas Medical, Inc., Halo Biosciences, Allysta Pharmaceuticals, Symic Bio.
What was QB3's most recent investment?
QB3's most recent investment on Caplight was in Kopra Bio in 2025.
What sectors does QB3 focus on?
QB3 focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Frontier & Industrial Tech.
What company stages does QB3 focus on?
Stage focus information for QB3 is not publicly available.
What is QB3's AUM?
QB3's assets under management are estimated between $50.0M and $100.0M.